1
|
Morii Y, Fujimoto S, Nakahara R, Okawa K, Senaha H, Fujiwara K, Tsubaki M, Matzno S, Takegami M, Shimomura K, Nishida S. Effect of proton pump inhibitors on the development of hypomagnesemia induced by panitumumab. Pharmazie 2022; 77:81-84. [PMID: 35209968 DOI: 10.1691/ph.2022.1988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Panitumumab, a therapeutic agent for unresectable advanced/recurrent colorectal cancer, is a human IgG2 monoclonal antibody that binds to and inhibits the activity of the epidermal growth factor receptor (EGFR). The onset of hypomagnesemia is a known side effect of anti-EGFR inhibitors, including panitumumab, and it is thought that inhibition of reabsorption of Mg in renal tubules is one of the causes. In addition, recent reports have shown that long-term administration of proton pump inhibitors (PPIs) reduces serum magnesium levels. Therefore, in this study, 102 patients who received oral PPIs treated with panitumumab were classified into a PPI combination group and a PPI non-combination group, and the effect of PPIs on the development of grade 2 or higher hypomagnesemia was investigated. The incidence of hypomagnesemia in the PPI combination group (46.9%, 15/32) was higher than that in the PPI non-combination group (25.7%, 18/70). A comparison of the backgrounds of the two groups of patients showed a significant difference in serum albumin levels. PPI administration was significantly associated with panitumumab-induced hypomagnesemia development when adjusted for known risk factors, serum albumin level, renal function, and oral magnesium oxide tablets in Cox proportional hazards regression analysis (hazard ratio 2.09; 95% confidence interval 1.03-4.22; P =0.040). These results indicate that detailed monitoring of serum magnesium levels is recommended for patients treated with panitumumab and co-administration of PPIs.
Collapse
Affiliation(s)
- Y Morii
- Department of Pharmacy, Ikeda City Hospital, Osaka, Japan; Division of Pharmacotherapy, Kindai University Faculty of Pharmacy, Osaka, Japan
| | - S Fujimoto
- Department of Pharmacy, Kindai University Hospital, Osaka, Japan
| | - R Nakahara
- Department of Pharmacy, Kindai University Hospital, Osaka, Japan
| | - K Okawa
- Department of Pharmacy, Ikeda City Hospital, Osaka, Japan
| | - H Senaha
- Department of Pharmacy, Ikeda City Hospital, Osaka, Japan
| | - K Fujiwara
- Department of Pharmacy, Kindai University Hospital, Osaka, Japan
| | - M Tsubaki
- Division of Pharmacotherapy, Kindai University Faculty of Pharmacy, Osaka, Japan
| | - S Matzno
- Division of Pharmaceutical Education, Kindai University Faculty of Pharmacy, Osaka, Japan
| | - M Takegami
- Department of Pharmacy, Kindai University Hospital, Osaka, Japan
| | - K Shimomura
- Department of Pharmacy, Ikeda City Hospital, Osaka, Japan
| | - S Nishida
- Division of Pharmacotherapy, Kindai University Faculty of Pharmacy, Osaka, Japan;,
| |
Collapse
|